The medical know-how sector has lengthy been characterised because the regular, dependable engine of the life sciences world.
A sector providing constant progress, with out the wild volatility and boom-or-bust narratives of biotech or the frothy hype of digital well being, it could be seen by some as “vanilla”, nevertheless it additionally has the advantage of being sturdy.
In a turbulent world financial system attributable to Trump’s tariffs, the battle in Ukraine and friction between the west and China, medtech is now driving a transformative pattern: the focus of large, “lumpy” funding capital, exemplified by offers just like the lately reported $18bn privatisation of Hologic by the personal fairness giants Blackstone and TPG.
Nevertheless, this inflow of capital just isn’t being distributed evenly throughout the globe. As a substitute, a geographic disparity is rising, with the US appearing as a strong magnet for this “lumpier” funding, whereas the UK and Europe wrestle to maintain tempo.
This transatlantic funding hole just isn’t an accident, however the logical end result of a US ecosystem that’s structurally optimised for scaling high-growth firms, whereas the European and UK techniques, regardless of world-class science, stay fragmented and risk-averse.
The size of the US capital markets, the depth of its personal fairness swimming pools, and an investor mindset geared in the direction of formidable scaling create a fertile floor for such transactions. In distinction, the UK and European monetary ecosystems are merely failing to maintain tempo.
The US enterprise capital fund is sort of twice the dimensions of its European counterpart, with a current evaluation displaying eight instances extra capital accessible for growth-stage firms within the US.
This preliminary drawback compounds over time. A 2025 evaluation highlighted that US VC funds achieved double the returns of these within the UK.
This efficiency hole creates a self-reinforcing cycle – greater returns appeal to extra capital, which permits greater bets, which in flip generates extra outsized returns.
European traders, usually dealing with extra risk-averse mandates and a much less unified market, have traditionally struggled to realize the identical velocity and scale of returns.
A promising UK or European medtech startup may efficiently navigate early-stage funding with seed and Collection A rounds. Nevertheless, in terms of the capital-intensive part of scaling – conducting large-scale scientific trials, constructing out industrial groups, and increasing into world markets – the native funding setting usually falls quick.
Because of this, profitable startups are pressured to hunt later-stage capital from the US. This often necessitates a “Delaware flip” – restructuring the corporate as a US entity – to attraction to American traders who’re extra acquainted and cozy with their very own company and authorized buildings.
In lots of circumstances, this monetary migration is adopted by a bodily one, with key operations and management transferring stateside, draining the native ecosystem of its most promising belongings.
The lately reported acquisition by personal fairness corporations Blackstone and TPG of medical diagnostics agency Hologic for $18.3bn, together with debt – the biggest medical units deal in nearly 20 years – exemplifies the present pattern amongst US VCs of creating mature, publicly-listed firms personal, optimising their operations away from the quarterly scrutiny of public markets, and reaping long-term, secure returns.
In Europe, whereas PE is energetic, the sheer dimension and audacity of such offers are uncommon. The European PE panorama is extra targeted on smaller, platform add-on investments fairly than transformative, multi-billion greenback take-privates of established champions.
Traditionally, Europe’s CE marking course of was usually seen as a quicker, extra easy path to market in contrast with the US Meals and Drug Administration (FDA). This was a key benefit for European innovators. Nevertheless, this dynamic has flipped.
The implementation of the European Union’s Medical Machine Regulation (MDR) was a response to high-profile gadget failures. Whereas well-intentioned, its execution has been extensively criticised for creating a fancy, expensive, and sluggish approval pathway.
A 2022 survey discovered that solely 22% of medtech executives discovered the EU approval course of predictable, in contrast with 62% for the FDA.
The MDR has created a bottleneck, with notified our bodies overwhelmed and lots of legacy units requiring re-certification. For a startup working on a decent funds, this regulatory uncertainty and elevated price could be deadly.
On the identical time, the FDA has undertaken vital reforms to make itself extra innovation pleasant.
Initiatives just like the breakthrough units programme present a clearer, extra collaborative, and infrequently quicker pathway for novel applied sciences that tackle unmet medical wants.
The FDA is now often perceived as a extra predictable and pragmatic associate than its European counterparts. For an investor betting a whole lot of thousands and thousands of {dollars}, regulatory predictability is non-negotiable. The US now presents that, whereas Europe presents a maze.
Brexit introduced the UK with a possibility to create world-leading, agile regulatory framework for medtech, however the present state of the sector is one in all uncertainty. Whereas the UK’s Medicines and Healthcare merchandise Regulatory Company (MHRA) has proposed formidable reforms, the tempo of implementation has been sluggish.
The UK’s particular challenges in market entry are additionally having a dampening impact on funding. The Voluntary Scheme for Branded Medicines Pricing and Entry (VPAS), with its excessive and unpredictable “clawback” charges on pharmaceutical revenues, has undermined investor confidence within the UK life sciences sector general.
The high-profile determination by Merck in September to scrap a deliberate £1bn UK enlargement, citing the unsure funding setting, is an instance. Whereas this instantly targets pharma, the sign it sends to the broader life sciences funding neighborhood, together with medtech, is profoundly adverse. It suggests a market that doesn’t persistently worth and reward innovation.
Subsequent 12 months marks the twenty fifth anniversary of the creation of Dolly the Sheep – the world’s first cloned animal – on the Roslin Institute, exterior Edinburgh. It’s a well timed reminder that the UK needs to be a worldwide chief in genomics and superior therapies like cell and gene remedy. In 2023, UK cell and gene remedy firms attracted round £200m in enterprise capital, a testomony to the standard of the underlying science.
The US is profitable this race not by luck, however by design. Its ecosystem – an enormous, unified market, deep and liquid capital swimming pools, a reformed and predictable regulator, and a tradition that celebrates scaling – is completely calibrated for the period of “lumpy” funding.
The medtech sector’s sturdy, defensive nature makes it a important asset for any superior financial system, promising high-skilled jobs and well being resilience.
For the UK and Europe to stay greater than only a supply of early-stage innovation for US giants to amass and scale, they need to transfer past diagnosing the issue and start the onerous work of rebuilding their ecosystems to compete within the new world of “lumpy” capital. The way forward for their medtech industries will depend on it.
“The transatlantic medtech funding hole: why does it exist and may it’s plugged?” was initially created and printed by Medical Machine Community, a GlobalData owned model.
The data on this web site has been included in good religion for common informational functions solely. It isn’t supposed to quantity to recommendation on which it is best to rely, and we give no illustration, guarantee or assure, whether or not categorical or implied as to its accuracy or completeness. You should receive skilled or specialist recommendation earlier than taking, or refraining from, any motion on the premise of the content material on our web site.
